Disitamab Vedotin in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07783815 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
20
Planned enrollment
2027-09-01
Primary-completion proxy
Executive view
NCT07783815 evaluates Disitamab Vedotin in HER2 Positive Muscle Invasive Bladder Carcinoma. The disclosed sponsor is Xiangya Hospital Central South University, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is The one-year recurrence-free survival rate of patients with high-risk NMIBC, assessed over One year after the treatment.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07783815 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider HER2 Positive Muscle Invasive Bladder Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Disitamab Vedotin, while Company & Deal Intelligence MCP organization_fetch was queried for Xiangya Hospital Central South University.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07783815 | Disitamab Vedotin | Phase 1 / Not yet recruiting | Xiangya Hospital Central South University | China | The one-year recurrence-free survival rate of patients with high-risk NMIBC One year after the treatment | 2027-09-01 |
| NCT07808216 | Toripalimab | Phase 2 / Not yet recruiting | Tianjin First Center Hospital | Geography not reported | Pathologic Complete Response (CR) Rate at 3 Months 3 months after the first dose of study treatment. | 2028-10-01 |
| NCT07804056 | Alpha-lactalbumin-oleic acid(Azanta A/S) | Phase 3 / Not yet recruiting | Hamlet BioPharma AB | Czechia | Event-Free Survival (EFS) From randomization until the occurrence of an EFS event or study comp… | 2029-07-01 |
| NCT07777848 | RAG-01 | Phase 2 / Not yet recruiting | Ractigen Therapeutics | China | Efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) 24 months | 2029-03-01 |
| NCT07747740 | Gemcitabine Hydrochloride | Phase 2 / Recruiting | N N Blokhin Russian Cancer Research Center | Russia | 12-Month Event-Free Survival 12 months after randomization | 2029-12-30 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07783815 is a Phase 1, not yet recruiting study with 20 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “The one-year recurrence-free survival rate of patients with high-risk NMIBC” over “One year after the treatment.” The retrieved endpoint description is: After all subjects have been enrolled and followed up for an additional 12 months, or upon achievement of the required number of positive events, Recurrence-Free Survival (RFS) will be analyzed using the Kaplan-Meier method. The median recurrence-free time will be estimated via the Kaplan-Meier method. Hazard ratios (HR) and their 95% confidence intervals will be calculated using the Cox proportional hazards model..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 20 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for HER2 Positive Muscle Invasive Bladder Carcinoma. These records do not establish direct evidence for NCT07783815 unless the registration number matches.
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Not Applicable; n=4; No numerical result field reported Source: https://clinicaltrials.gov/ct2/show/results/NCT02657486
UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
Phase 3; n=240; Adverse Event: dysuria = Treatment-emergent adverse events that occurred in ≥10% of enrolled patients (N = 240) was dysuria Source: https://pubmed.ncbi.nlm.nih.gov/41880645/
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Inva…
Phase 2; n=220; Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate = 46.4 percentage of participants (95% Confidence Interval, 27.5 - 66.1); Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate = 82.4 percentage of participants (95% Confidence Interval, 72.6 - 89.8) Source: https://clinicaltrials.gov/ct2/show/results/NCT04640623
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Disitamab Vedotin.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Xiangya Hospital Central South University. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Disitamab Vedotin is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07783815
Protocol source: https://clinicaltrials.gov/study/NCT07783815
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Disitamab Vedotin in HER2 Positive Muscle Invasive Bladder Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The one-year recurrence-free survival rate of patients with high-risk NMIBC and 2027-09-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
